Company · Biotech and pharma
Splice-switching oligonucleotide therapeutics for chronic inflammation
Melbourne, VIC
Every investor coverage indicates participated in a round Atisama Therapeutics raised.
Companies Atisama Therapeutics acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Ed Tucker | Chief Medical & Development Officer | IP Group Australia portfolio, Atisama Therapeutics team page |
Stories naming Atisama Therapeutics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Atisama Therapeutics reports its Phase 1 trial of RB042 advancing into multiple ascending dose cohorts, and appoints experienced biopharma executive Bernard Coulie as chair of its board.